Physician

Mani Nallasivan, M.D.

According to 2025 Medicare claims, Mani Nallasivan, M.D. (NPI: 1639171606) practices cardiology in the Merced, CA market, with the plurality of this provider's patient population coming from Merced, CA. This provider's primary affiliated billing organization is MANI NALLASIVAN M D INC A PROFESSIONAL CORPORATION (NPI: 1982977054; TIN: 770444355) and primary practice location at 95340-8499.

Nallasivan's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,595 traditional Medicare patients, billed 9,721 HCPCS/CPT codes, and received $747,941 in Medicare payments. The top billing code was 93306 (Ultrasound of heart with color-depicted blood flow, rate, direction and valve function). Part D data shows 3,214 prescription claims across 639 beneficiaries totaling $467,619 in drug costs, led by Xarelto (Rivaroxaban). DME data shows 61 claims. Open Payments data shows 33 records totaling $34,266. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has fallen sharply in recent years, from $2,080,735 to $747,941. In contrast, Part D prescription costs have moved from a lower plateau to a higher plateau, from $140,439 to $467,619. For DME billing, this smaller-volume category moved sharply higher in recent years, from $2,241 to $24,539.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,572	8,265	$2,080,735
2016	1,508	9,716	$2,538,250
2017	1,448	11,686	$2,882,162
2018	1,470	14,322	$1,355,992
2019	1,451	14,029	$1,361,740
2020	1,246	7,535	$1,122,715
2021	1,194	8,314	$1,001,590
2022	1,287	7,602	$883,909
2023	1,617	7,948	$620,181
2024	1,595	9,721	$747,941

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	336	1,678	$140,439
2016	354	1,811	$172,371
2017	359	1,655	$192,873
2018	361	1,726	$231,280
2019	392	1,779	$279,216
2020	411	2,098	$344,580
2021	500	2,368	$408,975
2022	522	2,474	$404,057
2023	585	2,680	$495,301
2024	639	3,214	$467,619

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	14	$1,986
2016	N/R	22	$1,645
2017	N/R	12	$583
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	17	$8,291
2024	N/R	61	$16,614

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
93306	Ultrasound of heart with color-depicted blood flow, rate, direction and valve function	422	424	$138
99203	New patient office or other outpatient visit with low level of medical decision making, if using time, 30 minutes or more	455	455	$78
78431	Nuclear medicine studies of blood flow in heart muscle at rest and with stress with concurrent ct scan	136	136	$69
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	1,281	2,252	$65
93000	Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report	133	160	$11

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xarelto	Rivaroxaban	153	10,170	$185,647
Eliquis	Apixaban	138	7,722	$144,301
Entresto	Sacubitril/Valsartan	15	1,110	$19,158
Repatha Sureclick	Evolocumab	11	924	$18,176
Brilinta	Ticagrelor	12	870	$12,388

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E0680	Non-pneumatic compression controller with sequential calibrated gradient pressure	Y	N/R	35	$16,021
E0679	Non-pneumatic sequential compression garment, half leg	Y	N/R	26	$593

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	30	$655	Amgen Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	3	$33,611	Janssen Research & Development, LLC
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Mani Nallasivan, M.D.?

Tedicare shows public-source Medicare data for Mani Nallasivan, M.D. (NPI 1639171606), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mani Nallasivan, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Mani Nallasivan, M.D.?

Mani Nallasivan, M.D. is linked to MANI NALLASIVAN M D INC A PROFESSIONAL CORPORATION (billing NPI 1982977054) in the available physician profile data.

Does Mani Nallasivan, M.D. have Open Payments data?

Mani Nallasivan, M.D. has 33 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.